AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33755978 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate (control group II)
Number of subjects: 120
Study 35084893 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-focused therapy (FFT) for 4 months
Number of subjects: 119
Study 35084893 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-focused therapy (FFT)
Number of subjects: 119
Study 35084893 — intervention group
Group type: COMPARATOR
Intervention: Enhanced care (EC)
Number of subjects: 119
Study 32017856 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose prolotherapy + Short Wave Diathermy (SWD)
Number of subjects: 63
Study 32017856 — intervention group
Group type: COMPARATOR
Intervention: Dextrose prolotherapy with sham SWD
Number of subjects: 63
Study 34158133 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoprotectant with pentoxifylline
Number of subjects: 68
Study 34158133 — intervention group
Group type: COMPARATOR
Intervention: Cryoprotectant without pentoxifylline
Number of subjects: 68
Study 34530894 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based Problem Management Plus (group PM+) with antidepressant therapy (ADT)
Number of subjects: 420
Study 34530894 — intervention group
Group type: COMPARATOR
Intervention: Usual care (baseline chronic care services)
Number of subjects: 420
Study 34530894 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness model
Number of subjects: 420
Study 35690556 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/ledipasvir
Number of subjects: 190
Study 35690556 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Number of subjects: 190
Study 35690556 — intervention group
Group type: COMPARATOR
Intervention: Standard Care Treatment (SCT)
Number of subjects: 190
Study 34396571 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 µg εPA‐44
Number of subjects: 360
Study 34396571 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 µg εPA‐44
Number of subjects: 360
Study 34396571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 34229888 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA/HIV62B alone (T1; n = 4)
Number of subjects: 27
Study 34229888 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA/HIV62B and AIDSVAX B/E (T2; n = 4)
Number of subjects: 27
Study 34229888 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA/HIV62B alone (T3; n = 6)
Number of subjects: 27
Study 34229888 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA/HIV62B and AIDSVAX B/E (T4; n = 6)
Number of subjects: 27
Study 34229888 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E alone (T5; n = 7)
Number of subjects: 27
Study 36380348 — intervention group
Group type: EXPERIMENTAL
Intervention: Anapana meditation
Number of subjects: 0
Study 36380348 — intervention group
Group type: EXPERIMENTAL
Intervention: Body scan meditation
Number of subjects: 0
Study 36380348 — intervention group
Group type: EXPERIMENTAL
Intervention: Metta meditation
Number of subjects: 0
Study 36380348 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 36380348 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (Anapana, Body Scan, Metta)
Number of subjects: 0
Study 33835256 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride Varnish (DuraphatTM, 5% NaF)
Number of subjects: 55
Study 33835256 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol Varnish (20% xylitol)
Number of subjects: 55
Study 33835256 — intervention group
Group type: COMPARATOR
Intervention: Placebo Varnish (no F/Xylitol)
Number of subjects: 55
Study 34653953 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02% HOCl nasal spray three times a day for two months
Number of subjects: 78
Study 34653953 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS) nasal irrigation
Number of subjects: 78
Study 33403697 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal adalimumab (40 mg, 0.4 mL)
Number of subjects: 24
Study 33403697 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous adalimumab (40 mg)
Number of subjects: 24
Study 33429151 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR)
Number of subjects: 1084
Study 34621450 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Medication Review by Community Pharmacists (HMR‐CP)
Number of subjects: 166
Study 34621450 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 166
Study 35652296 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich algae oil
Number of subjects: 528
Study 35652296 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich algae oil (for neonates born <27 weeks' GA)
Number of subjects: 528
Study 35652296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 528
Study 33434700 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting intervention delivered through health services in Jamaica from age 3 to 18 months.
Number of subjects: 262
Study 33434700 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial trial benefits at 18 months (effect size 0.34–0.38 standard deviation).
Number of subjects: 262
Study 32387542 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanus toxoid (TT) vaccine
Number of subjects: 0
Study 32387542 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified protein derivative of Mycobacterium tuberculosis (PPD)
Number of subjects: 0
Study 32387542 — intervention group
Group type: EXPERIMENTAL
Intervention: Sm infection
Number of subjects: 0
Study 32387542 — intervention group
Group type: EXPERIMENTAL
Intervention: Nematode infection
Number of subjects: 0
Study 32387542 — intervention group
Group type: COMPARATOR
Intervention: Urban-rural comparison
Number of subjects: 0
Study 35091050 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (400-600 mg)
Number of subjects: 71
Study 35091050 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (1.0-1.2 mEq/L)
Number of subjects: 71
Study 35091050 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 71
Study 32224716 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) using 220 mm Hg
Number of subjects: 16
Study 32224716 — intervention group
Group type: COMPARATOR
Intervention: Cuff control protocol with 20 mm Hg (CUFF)
Number of subjects: 16
Study 32224716 — intervention group
Group type: COMPARATOR
Intervention: No IPC (control) (CON)
Number of subjects: 16
Study 35719216 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine-prilocaine (EMLA®)
Number of subjects: 72
Study 35719216 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 72
Study 35373776 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based psychosocial therapy program via smartphone for 6 weeks
Number of subjects: 209
Study 35373776 — intervention group
Group type: COMPARATOR
Intervention: Control group with access to self-help audiovisual material
Number of subjects: 209
Study 33950184 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-delivered pill packs in prepackaged blisters
Number of subjects: 80
Study 33950184 — intervention group
Group type: COMPARATOR
Intervention: Routine pharmacy prescriptions (Control)
Number of subjects: 80
Study 32840201 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-impregnated ceramic water filter
Number of subjects: 404
Study 32840201 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-impregnated ceramic tablet
Number of subjects: 404
Study 32840201 — intervention group
Group type: COMPARATOR
Intervention: Safe-storage water container
Number of subjects: 404
Study 32840201 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 404
Study 35048793 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcome-based telehealth follow-up by a rheumatologist (PRO-TR)
Number of subjects: 294
Study 35048793 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcome-based telehealth follow-up by a nurse (PRO-TN)
Number of subjects: 294
Study 35048793 — intervention group
Group type: COMPARATOR
Intervention: Conventional outpatient follow-up (control)
Number of subjects: 294
Study 33582566 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity/exercise
Number of subjects: 417
Study 35135006 — intervention group
Group type: EXPERIMENTAL
Intervention: D-allulose
Number of subjects: 18
Study 35135006 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythritol
Number of subjects: 18
Study 35135006 — intervention group
Group type: COMPARATOR
Intervention: Lactisole
Number of subjects: 18
Study 35135006 — intervention group
Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 18
Study 34930206 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on Watson's Theory of Human Caring
Number of subjects: 101
Study 34930206 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 101
Study 34930206 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 101
Study 35717048 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-adapted intraoperative radiation therapy (IORT)
Number of subjects: 0
Study 35717048 — intervention group
Group type: COMPARATOR
Intervention: External beam radiation therapy (control)
Number of subjects: 0
Study 33239101 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 506
Study 33239101 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 506
Study 34256114 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training in hypoxia (RTH)
Number of subjects: 54
Study 34256114 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training in normoxia (RTN)
Number of subjects: 54
Study 34256114 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 54
Study 32653666 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized patient
Number of subjects: 0
Study 32653666 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity simulation
Number of subjects: 0
Study 32653666 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial task trainer
Number of subjects: 0
Study 34942106 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention
Number of subjects: 42
Study 34942106 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 42
Study 32348638 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled steroids (IS) before weaning
Number of subjects: 174
Study 32348638 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled steroids (IS) after weaning
Number of subjects: 174
Study 32348638 — intervention group
Group type: COMPARATOR
Intervention: No inhaled steroids (IS)
Number of subjects: 174
Study 32348638 — intervention group
Group type: COMPARATOR
Intervention: NICU clinics
Number of subjects: 174
Study 32348638 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary clinics
Number of subjects: 174
Study 34910554 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomically directed therapy (arm A)
Number of subjects: 193
Study 34910554 — intervention group
Group type: COMPARATOR
Intervention: Treatment of physician choice (TPC) (arm B)
Number of subjects: 193
Study 34910554 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating tumor DNA status
Number of subjects: 193
Study 32060099 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose icotinib (250 mg, thrice daily; L858R-HD)
Number of subjects: 253
Study 32060099 — intervention group
Group type: COMPARATOR
Intervention: Routine-dose icotinib (125 mg, thrice daily; L858R-RD)
Number of subjects: 253
Study 32060099 — intervention group
Group type: COMPARATOR
Intervention: Routine-dose icotinib (125 mg, thrice daily; 19-Del-RD)
Number of subjects: 253
Study 32060099 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose icotinib (L858R-HD)
Number of subjects: 253
Study 32060099 — intervention group
Group type: COMPARATOR
Intervention: Routine-dose icotinib (L858R-RD)
Number of subjects: 253
Study 32060099 — intervention group
Group type: COMPARATOR
Intervention: Routine-dose icotinib (19-Del-RD)
Number of subjects: 253
Study 32060099 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 253
Study 35113435 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training three times per week for 12 weeks along with a balanced diet
Number of subjects: 40
Study 35113435 — intervention group
Group type: COMPARATOR
Intervention: Balanced diet only
Number of subjects: 40
Study 34489267 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care supplemented with vertebroplasty
Number of subjects: 100
Study 34489267 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 32997237 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 2075
Study 34971579 — intervention group
Group type: COMPARATOR
Intervention: Low-dose hydroxyurea (10 mg/kg per day)
Number of subjects: 220
Study 34971579 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose hydroxyurea (20 mg/kg per day)
Number of subjects: 220
Study 33950156 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained care (SusC) smoking cessation intervention
Number of subjects: 342
Study 33950156 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) smoking cessation intervention
Number of subjects: 342
Study 32892320 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina (6 g/day for 7 days)
Number of subjects: 11
Study 32892320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 36852512 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate removal of urinary catheter
Number of subjects: 693
Study 36852512 — intervention group
Group type: COMPARATOR
Intervention: Delayed removal of urinary catheter
Number of subjects: 693
Study 32745555 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab with azathioprine or mycophenolate mofetil
Number of subjects: 39
Study 32745555 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment with immunosuppressive therapy
Number of subjects: 39
Study 32745555 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy
Number of subjects: 39
Study 32810146 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples' UBL
Number of subjects: 6770
Study 32810146 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's UBL
Number of subjects: 6770
Study 32810146 — intervention group
Group type: EXPERIMENTAL
Intervention: Men's UBL
Number of subjects: 6770
Study 32810146 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 6770
Study 36250608 — intervention group
Group type: EXPERIMENTAL
Intervention: Music enrichment program (Music Together®)
Number of subjects: 90
Study 36250608 — intervention group
Group type: COMPARATOR
Intervention: Active play date control
Number of subjects: 90
Study 33471029 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic echocardiographic screening followed by secondary antibiotic prophylaxis
Number of subjects: 3973
Study 33471029 — intervention group
Group type: COMPARATOR
Intervention: No echocardiographic screening
Number of subjects: 3973
Study 34688520 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocrystalline silver dressings
Number of subjects: 100
Study 34688520 — intervention group
Group type: COMPARATOR
Intervention: 1% silver sulfadiazine dressings
Number of subjects: 100
Study 32213659 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (TRT) - Testosterone undecanoate injection three times/6 months (n = 20)
Number of subjects: 41
Study 32213659 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 21)
Number of subjects: 41
Study 34653515 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut Epicutaneous Immunotherapy (49 participants)
Number of subjects: 226
Study 34653515 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg Oral Immunotherapy or Baked Egg Diet (92 participants)
Number of subjects: 226
Study 34653515 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline type 2 cells
Number of subjects: 226
Study 34653515 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline egg-specific type 2 cell frequency
Number of subjects: 226
Study 35291842 — intervention group
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve group (PENG) block
Number of subjects: 60
Study 35291842 — intervention group
Group type: COMPARATOR
Intervention: Femoral nerve block (FNB)
Number of subjects: 60
Study 32493387 — intervention group
Group type: EXPERIMENTAL
Intervention: MIPS
Number of subjects: 12
Study 32493387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 35350000 — intervention group
Group type: EXPERIMENTAL
Intervention: AFCs + collagen
Number of subjects: 10
Study 35350000 — intervention group
Group type: COMPARATOR
Intervention: AFCs only
Number of subjects: 10
Study 34464306 — intervention group
Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.5 mg/kg plus 1?g/kg dexmedetomidine and 0.9% isotonic (Group 4)
Number of subjects: 60
Study 34464306 — intervention group
Group type: COMPARATOR
Intervention: levobupivacaine 0.5 mg/kg plus 0.9% isotonic (Group 2)
Number of subjects: 60
Study 34464306 — intervention group
Group type: COMPARATOR
Intervention: 1?g/kg dexmedetomidine plus 0.9% isotonic (Group 3)
Number of subjects: 60
Study 34464306 — intervention group
Group type: COMPARATOR
Intervention: 0.9% isotonic 20 ml (Group 1)
Number of subjects: 60
Study 34893026 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia with patient-controlled intravenous analgesia (PCIA)
Number of subjects: 120
Study 34893026 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia with patient-controlled epidural analgesia (PCEA)
Number of subjects: 120
Study 34893026 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia with continuous erector spinae plane block (ESPB) and PCIA
Number of subjects: 120
Study 33808849 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Thai Massage (TTM) - six weekly 1‐h sessions
Number of subjects: 12
Study 33808849 — intervention group
Group type: COMPARATOR
Intervention: Rest (Control)
Number of subjects: 12
Study 32458080 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 308-nm excimer lamp and topical mometasone furoate cream
Number of subjects: 16
Study 32458080 — intervention group
Group type: COMPARATOR
Intervention: 308-nm excimer lamp alone (monotherapy)
Number of subjects: 16
Study 32458080 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 16
Study 34620069 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine/Ketamine (DK)
Number of subjects: 64
Study 34620069 — intervention group
Group type: COMPARATOR
Intervention: Propofol/Fentanyl (PF)
Number of subjects: 64
Study 35262401 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-lumen flexible ureteroscope (DLFU)
Number of subjects: 79
Study 35262401 — intervention group
Group type: COMPARATOR
Intervention: Single-lumen flexible ureteroscope (SLFU)
Number of subjects: 79
Study 32450253 — intervention group
Group type: EXPERIMENTAL
Intervention: SLSI-1216
Number of subjects: 0
Study 36454561 — intervention group
Group type: EXPERIMENTAL
Intervention: BRIGHT (tele-cognitive behavioral therapy)
Number of subjects: 44
Study 36454561 — intervention group
Group type: COMPARATOR
Intervention: Attention Control (AC)
Number of subjects: 44
Study 33694141 — intervention group
Group type: EXPERIMENTAL
Intervention: Mercurius corrosivus (Merc-c.) at potency levels 24x-30x
Number of subjects: 0
Study 33694141 — intervention group
Group type: COMPARATOR
Intervention: Water controls (unsuccussed or succussed water)
Number of subjects: 0
Study 32271671 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoendocrine therapy (CT+E)
Number of subjects: 552
Study 32271671 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy alone (E)
Number of subjects: 552
Study 35416182 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g fish oil daily for 6 weeks
Number of subjects: 68
Study 35416182 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g soybean oil daily for 6 weeks
Number of subjects: 68
Study 35416182 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g each fish and soybean oil daily for 6 weeks
Number of subjects: 68
Study 35416182 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline mtDNA gene expression
Number of subjects: 68
Study 35416182 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in mtDNA gene expression
Number of subjects: 68
Study 32739509 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulodexide (oral dose twice a day for 7 days before sclerotherapy, continued for 3 months)
Number of subjects: 720
Study 32739509 — intervention group
Group type: COMPARATOR
Intervention: Standard sclerotherapy protocol (Polidocanol as sclerosing agent, 20 to 30 mm Hg compression stockings for 7 days)
Number of subjects: 720
Study 32739509 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulodexide
Number of subjects: 720
Study 32739509 — intervention group
Group type: COMPARATOR
Intervention: Standard sclerotherapy protocol
Number of subjects: 720
Study 32739509 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulodexide and Standard sclerotherapy
Number of subjects: 720
Study 35972853 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PrEP
Number of subjects: 260
Study 32222821 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Number of subjects: 324
Study 32222821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study 32222821 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 324
Study 32478030 — intervention group
Group type: EXPERIMENTAL
Intervention: Video treatment group (watching a 5-min video about the possible health hazards of MP use)
Number of subjects: 703
Study 32478030 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 703
Study 34023515 — intervention group
Group type: EXPERIMENTAL
Intervention: HN-STAR intervention
Number of subjects: 0
Study 32666067 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber posts (FRC Postec Plus, Ivoclar Vivadent) luted using self‐adhesive composite cement (SpeedCEM Plus, Ivoclar Vivadent)
Number of subjects: 20
Study 32666067 — intervention group
Group type: COMPARATOR
Intervention: Control group: Root canals sealed using Acroseal (Septodont, France) and gutta‐percha, followed by composite resin for coronal restoration (Evetric, Ivoclar Vivadent)
Number of subjects: 20